» Articles » PMID: 22984265

14-3-3ε and 14-3-3σ Inhibit Toll-like Receptor (TLR)-mediated Proinflammatory Cytokine Induction

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2012 Sep 18
PMID 22984265
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Toll-like receptors (TLRs) are a group of pattern recognition receptors that play a crucial role in the induction of the innate immune response against bacterial and viral infections. TLR3 has emerged as a key sensor of viral double-stranded RNA. Thus, a clearer understanding of the biological processes that modulate TLR3 signaling is essential. Limited studies have applied proteomics toward understanding the dynamics of TLR signaling. Herein, a proteomics approach identified 14-3-3ε and 14-3-3σ proteins as new members of the TLR signaling complex. Toward the functional characterization of 14-3-3ε and 14-3-3σ in TLR signaling, we have shown that both of these proteins impair TLR2, TLR3, TLR4, TLR7/8, and TLR9 ligand-induced IL-6, TNFα, and IFN-β production. We also show that 14-3-3ε and 14-3-3σ impair TLR2-, TLR3-, TLR4-, TLR7/8-, and TLR9-mediated NF-κB and IFN-β reporter gene activity. Interestingly, although the 14-3-3 proteins inhibit poly(I:C)-mediated RANTES production, 14-3-3 proteins augment Pam(3)CSK(4), LPS, R848, and CpG-mediated production of RANTES (regulated on activation normal T cell expressed and secreted) in a Mal (MyD88 adaptor-like)/MyD88-dependent manner. 14-3-3ε and 14-3-3σ also bind to the TLR adaptors and to both TRAF3 and TRAF6. Our study conclusively shows that 14-3-3ε and 14-3-3σ play a major regulatory role in balancing the host inflammatory response to viral and bacterial infections through modulation of the TLR signaling pathway. Thus, manipulation of 14-3-3 proteins may represent novel therapeutic targets for inflammatory conditions and infections.

Citing Articles

Recent advancements in the diverse roles of polymerase-associated proteins in the replication and pathogenesis of Newcastle disease virus.

Zhou J, Duan Y, Liu M, Liu J, Hu Z, Duan Z Vet Res. 2025; 56(1):8.

PMID: 39800751 PMC: 11726954. DOI: 10.1186/s13567-024-01429-0.


Risk factors for inhibitors in hemophilia A based on RNA-seq and DNA methylation.

Liu W, Lyu C, Wang W, Xue F, Chen L, Li H Res Pract Thromb Haemost. 2022; 6(6):e12794.

PMID: 36090157 PMC: 9445143. DOI: 10.1002/rth2.12794.


Molecular characterisation, expression and functional feature of TRAF6 in the King pigeon ().

Guo Y, Xu Y, Xiong D, Zhou Y, Kang X, Meng C Innate Immun. 2020; 26(6):490-504.

PMID: 32393097 PMC: 7491236. DOI: 10.1177/1753425920920930.


A Structure-Informed Atlas of Human-Virus Interactions.

Lasso G, Mayer S, Winkelmann E, Chu T, Elliot O, Patino-Galindo J Cell. 2019; 178(6):1526-1541.e16.

PMID: 31474372 PMC: 6736651. DOI: 10.1016/j.cell.2019.08.005.


Myosin IIA Regulated Tight Junction in Oxygen Glucose-Deprived Brain Endothelial Cells Via Activation of TLR4/PI3K/Akt/JNK1/2/14-3-3ε/NF-κB/MMP9 Signal Transduction Pathway.

Lv Y, Liu W, Ruan Z, Xu Z, Fu L Cell Mol Neurobiol. 2019; 39(2):301-319.

PMID: 30666520 PMC: 11479604. DOI: 10.1007/s10571-019-00654-y.


References
1.
Kumar D, Hosse J, von Toerne C, Noessner E, Nelson P . JNK MAPK pathway regulates constitutive transcription of CCL5 by human NK cells through SP1. J Immunol. 2009; 182(2):1011-20. DOI: 10.4049/jimmunol.182.2.1011. View

2.
Scanzello C, Plaas A, Crow M . Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound?. Curr Opin Rheumatol. 2008; 20(5):565-72. DOI: 10.1097/BOR.0b013e32830aba34. View

3.
Bouwmeester T, Bauch A, Ruffner H, Angrand P, Bergamini G, Croughton K . A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol. 2004; 6(2):97-105. DOI: 10.1038/ncb1086. View

4.
McCormack W, Parker A, ONeill L . Toll-like receptors and NOD-like receptors in rheumatic diseases. Arthritis Res Ther. 2009; 11(5):243. PMC: 2787278. DOI: 10.1186/ar2729. View

5.
Zhao J, Meyerkord C, Du Y, Khuri F, Fu H . 14-3-3 proteins as potential therapeutic targets. Semin Cell Dev Biol. 2011; 22(7):705-12. PMC: 3207012. DOI: 10.1016/j.semcdb.2011.09.012. View